NNovartis Read More Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy2026-11-03 Novartis CEO Vas Narasimhan backs the company’s current M&A strategy, which is mainly focused on bolt-on deals under…
NNovartis Read More A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team2026-09-25 On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called…
NNovartis Read More Novartis investors turn spotlight on M&A after trial setbacks2026-09-11 By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis Read More Novartis investors turn spotlight on M&A after trial setbacks2026-09-11 By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis Read More Novartis investors turn spotlight on M&A after trial setbacks2026-09-11 By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis Read More Novartis’s Pipeline Just Lost Two Big Bets2026-09-08 Novartis’s Pipeline Just Lost Two Big Bets – Moby THE GIST Our analysts just identified a stock with…
NNovartis Read More Novartis’s Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance2026-08-19 A Platform Bet on Radiation The most consequential idea in Fiona Marshall’s vision for Novartis research is also…
NNovartis Read More Novartis says rare muscle disease drug shows promise in early trial2026-06-15 June 11 (Reuters) – Novartis said on Thursday an experimental drug, which it acquired as part of its…
NNovartis Read More Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth2026-06-14 Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
NNovartis Read More Novartis RNA drug acquired in $12B Avidity deal notches a trial win2026-06-11 This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
NNovartis Read More Novartis $12bn bet on Avidity well placed after mid-stage FSHD win2026-06-11 Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets,…
NNovartis Read More Novartis Reshapes Growth With Biotech Deals And AI Powered R&D Push2026-04-30 Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…